Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Amgen Inc. (NASDAQ: AMGN).

Full DD Report for AMGN

You must become a subscriber to view this report.


Recent News from (NASDAQ: AMGN)

FDA Approves Aimovig(TM) (erenumab-aooe), A Novel Treatment Developed Specifically For Migraine Prevention
THOUSAND OAKS, Calif. , May 17, 2018 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig™ (erenumab-aooe) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approac...
Source: PR Newswire
Date: May, 17 2018 19:04
Your Daily Pharma Scoop: Loxo Outstanding Results, Cimzia Trial Success, Audentes Positive Data
Analysis focus: LOXO Loxo Oncology (LOXO), which was recently covered in a series of excellent articles by our very own Dr. Zach Hartman, PhD, who collaborates with the Total Pharma Tracker and whose members saw an early view of the series (...and so on), is up strongly “following...
Source: SeekingAlpha
Date: May, 17 2018 12:00
Biotechs perk up ahead of ASCO abstract drop
The SPDR S&P Biotech ETF ( XBI +1.1% ) is up  1%  as investors ramp up buying ahead of the abstract drop for the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 1 - 5. More news on: SPDR Biotech ETF, Celgene Corporation, bluebird bio, Inc., He...
Source: SeekingAlpha
Date: May, 16 2018 12:56
Eli Lilly Had Good Reason To Spend $1.6B On Armo
Eli Lilly’s ( LLY ) $1.6 billion purchase of Armo Biosciences ( ARMO ) last week has deeper implications than simply making Armo shareholders richer. More important than that, it is a vote of confidence in an approach casting an ever wider net of combining cancer immunotherapies with an...
Source: SeekingAlpha
Date: May, 16 2018 11:24
Expanded label for Amgen's Repatha approved in Europe
The European Commission approves Amgen's (NASDAQ: AMGN ) Repatha (evolocumab) for adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering low-density lipoprotein cholesterol (LDL...
Source: SeekingAlpha
Date: May, 16 2018 09:18
Amgen Receives European Commission Approval For Repatha® (Evolocumab) To Prevent Heart Attack And Stroke In Adults With Established Cardiovascular Disease
THOUSAND OAKS, Calif. , May 16, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication in the Repatha ® (evolocumab) label for adults with established atherosclerotic cardiovascular disease (myocardial infarction...
Source: PR Newswire
Date: May, 16 2018 09:00
Commercial Success Following FDA Clearance Could Indicate 250% or More In Upside for BTCY Shareholders
- Intuitive Surgical (ISRG) and ResMed (RMD) have both executed flawlessly, leaving their counterparts in the dust - early investors have made out tremendously well. - Up-and-coming BTCY could look similar in a short time. Their product launch is underway and appears to be ahead of sc...
Source: Livemoney
Date: May, 16 2018 07:41
Eli Lilly's Positive Phase 3 Results Along With Recent Acquisitions Makes It A Force To Be Reckoned With
Recently, Eli Lilly ( LLY ) announced that it had obtained positive results in one of its two phase 3 studies treating patients with headaches. This sets the ability to talk to the FDA for the next steps available, to possibly get galcanezumab to market for these patients. This news come...
Source: SeekingAlpha
Date: May, 16 2018 07:38
FDA OKs Pfizer's Epogen/Procrit biosimilar
The FDA approves Pfizer ( PFE -1% ) unit Hospira's Retacrit (epoetin alfa-epbx), a biosimilar of Amgen's ( AMGN -2.5% ) Epogen/Procrit. More news on: Pfizer Inc., Amgen Inc., Healthcare stocks news, Stocks on the move, Read more ...
Source: SeekingAlpha
Date: May, 15 2018 12:06
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, ...
Source: SeekingAlpha
Date: May, 14 2018 12:27

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-17173.31174.65175.43172.532,268,360
2017-06-20165.43166.29168.70164.793,857,863
2017-06-19163.10165.09165.22162.693,043,884
2017-06-16163.84162.42164.10161.135,887,244
2017-06-15164.24164.11164.90162.553,585,036

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-13203,319328,45461.9018Short
2018-08-10182,421321,37956.7620Short
2018-08-09278,079598,00146.5014Short
2018-08-08391,281650,38260.1617Short
2018-08-07199,939404,44949.4349Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on AMGN.


About Amgen Inc. (NASDAQ: AMGN)

Logo for Amgen Inc. (NASDAQ: AMGN)

Not available

 

Contact Information

 

 

Current Management

  • Richard Nanula / CFO
  • Steven M. Odre / Secretary

Current Share Structure

  • Market Cap: $116,433,788,992 - 05/14/2018
  • Issue and Outstanding: 661,706,007 - 04/18/2018

 


Recent Filings from (NASDAQ: AMGN)

Filing Type: CT ORDERFiling Source: edgar
Filing Date: May, 17 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 26 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 25 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 24 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: April, 12 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 11 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: April, 11 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (NASDAQ: AMGN)

Daily Technical Chart for (NASDAQ: AMGN)


Stay tuned for daily updates and more on (NASDAQ: AMGN)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: AMGN)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AMGN is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of AMGN and does not buy, sell, or trade any shares of AMGN. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/